Philippe Pouletty, M.D., CEO of Truffle Capital and Founder of Carvolix, describes the evolution of heart valve replacement and the significance of AI-guided robotics in expanding access to transcatheter procedures. The company's biomimetic mitral valve and AI software that guides valve placement using a mini robot are making these procedures safer and easier for less experienced cardiologists to perform. The technology is also being adapted to treat brain strokes by enabling a larger pool of cardiologists to quickly perform necessary interventions.

Philippe explains, "At Truffle Capital, are what we like to call ourselves Business Builders, which is to say we're not just going to start small companies, we are going to try and build world leaders to revolutionize medicine. For Carvolix, this means interventional cardiology as well as the treatment of brain strokes. As you know, replacing heart valves is a major medical need. We have four heart valves that open and close 50 to 100 times per minute, which can get calcified and dysfunctional with time and need replacement. So 40 years ago, you would go to a skilled surgeon who would say, "Okay, I'm going to open your chest. I'm going to stop your heart, and I'm going to sew a new valve."

"But recently we decided to lead the new revolution, which is a small robot based on artificial intelligence, that could autonomously, under the clinical supervision of a cardiologist, replace a valve. We think that this new revolution is going to allow many more patients to benefit from aortic, mitral, and tricuspid valve replacement, even in smaller cardiac centers and among younger cardiologists. A similar revolution happened in the cockpit of Boeing and Airbus planes when the autopilot, the GPS systems, and satellite systems brought autonomy to planes."

#Carvolix #CardiacNews #PatientCare #HealthTech #Cardio #AIinHealthcare #InterventionalCardiology #StrokeCare #MedTechInnovation #RoboticsInMedicine #TAVI #Thrombectomy #DigitalHealth

Carvolix.eu

Download the transcript here